While the reduction in price target from $24 to $20 by Alliance Global Partners could suggest a tempered outlook on Ocuphire Pharma's future price performance, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal might lead to a neutral short-term impact on OCUP's stock price as investors weigh the lowered price target against the retained positive rating.